drugset
drugset / Trial / NCT01606748

A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin

NCT01606748 ↗

Phase 2 Completed 35 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.

Timeline

Start
2012-08
Primary completion
2013-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1250 mg/m2 Intravenous
Subject Necitumumab Monoclonal antibody 800 mg Intravenous

Indications

cancer